AK Global Asset Management LLC Buys New Shares in AbbVie Inc. $ABBV

AK Global Asset Management LLC bought a new stake in shares of AbbVie Inc. (NYSE:ABBV) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 39,645 shares of the company’s stock, valued at approximately $9,058,000. AbbVie comprises approximately 7.9% of AK Global Asset Management LLC’s investment portfolio, making the stock its 3rd biggest holding.

A number of other hedge funds also recently made changes to their positions in ABBV. Evolution Wealth Management Inc. acquired a new position in shares of AbbVie in the 2nd quarter valued at $26,000. Chelsea Counsel Co. acquired a new position in shares of AbbVie in the 3rd quarter valued at $26,000. Westend Capital Management LLC acquired a new position in shares of AbbVie in the 4th quarter valued at $29,000. Texas Capital Bancshares Inc TX acquired a new position in shares of AbbVie in the 3rd quarter valued at $31,000. Finally, Caitlin John LLC acquired a new position in shares of AbbVie in the 3rd quarter valued at $33,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. William Blair restated an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Wall Street Zen upgraded shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 28th. UBS Group dropped their price objective on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a research note on Thursday, February 5th. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, January 21st. Finally, Piper Sandler increased their price objective on shares of AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $253.15.

AbbVie Trading Down 0.2%

ABBV opened at $206.21 on Wednesday. The stock has a market capitalization of $364.61 billion, a PE ratio of 87.38, a PEG ratio of 0.73 and a beta of 0.38. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81. The firm has a 50-day moving average price of $220.95 and a two-hundred day moving average price of $224.28.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter last year, the company posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 3.4%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is 293.22%.

Insider Activity

In other news, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. This trade represents a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.25% of the stock is currently owned by company insiders.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: JPMorgan calls the recent pullback a buying opportunity and reiterates confidence with a $260 price target, arguing valuation and long‑term cash flow from immunology and aesthetics create upside for ABBV. AbbVie Gets JPMorgan Buying Opportunity Call
• Positive Sentiment: Allergan Aesthetics (an AbbVie unit) opened a new AMI training center in Austin, strengthening commercial support and physician training for aesthetics products — a gradual, supportive tailwind for the aesthetics portfolio. Allergan Aesthetics Third AMI Center Opens
• Neutral Sentiment: AbbVie updated an ongoing real‑world Parkinson’s observational study in Belgium — progress on neurology evidence can support longer‑term pipeline value, but this is an informational update without immediate commercial impact. AbbVie’s Real‑World Parkinson’s Study
• Neutral Sentiment: Analyst coverage is mixed but constructive: the stock retains an average “Moderate Buy” rating, and several articles revisit valuation, dividend yield and upcoming Q1 earnings (April 29) as key decision points for investors. These views temper panic but don’t change fundamentals immediately. Analyst Average Rating
• Negative Sentiment: AbbVie agreed to list Humira on the TrumpRx discount program at an ~86% discount under a White House pricing pact — this is a major pricing concession for a legacy blockbuster and increases near‑term revenue risk and valuation uncertainty for the post‑exclusivity Humira franchise. AbbVie Puts Humira on TrumpRx
• Negative Sentiment: AbbVie lowered its Q1 and FY‑2026 outlook after taking a $744M R&D charge — the guide cut and one‑time charge weigh on near‑term EPS trajectory and help explain recent share weakness. AbbVie Lowers Q1 and FY‑2026 Outlook
• Negative Sentiment: Market commentary and headlines note ABBV underperformed peers and shares have pulled back ~12% over the past month — amplifying investor sensitivity to guidance, Humira pricing moves, and upcoming earnings. AbbVie Stock Drops Despite Market Gains

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.